Contributions
Abstract: EP1687
Type: ePoster
Abstract Category: Therapy - disease modifying - 28 Long-term treatment monitoring
Objective: To study the long-term real-life use of interferon β1-a sc tiw in relapsing remitting multiple sclerosis (RRMS) patients, and to investigate the duration of the treatment periods, the causes of treatment cessation, and changes in expanded disability status scale (EDSS).
Methods: Clinical data was drawn in two population based cohorts diagnosed for RRMS during 1990 to 2010 and 2010 to 2014. Patients treated with interferon β1-a sc tiw at the Tampere District University Hospital in Finland were included in the study. Baseline characteristics and study endpoints were summarized using descriptive statistics.
Results: Of the 680 patients diagnosed during 1990-2010, a total of 293 initiated with interferon β1-a sc tiw. The average first treatment period lasted 2.9 years (standard deviation SD 2.89). The EDSS at treatment start was 1.7 (mean, SD 1.56) and 3.4 at the follow up of 6.8 years (mean, SD 4.1).Of the 209 patients diagnosed during 2010-2014, a total of 68 initiated with interferon β1-a sc tiw. The average first treatment period lasted 2.1 years (SD 1.55). The EDSS at treatment start was 0.9 (mean, SD 1.08) and 1.3 at the follow up of 2.2 years (mean, SD 1.3).Of the 361 patients in both cohorts, 39.1 % of the patients did not switch treatment. A total of 36.1% switched treatment once. The activation of the disease was the most common cause for cessation of the treatment (24.1%). Other factors were low MXA titer (12.2%) and side effects (11.9%).A total of 53.7% did not have any treatment interruptions, 32.4% had one interruption.
Conclusions: Long-term compliance to treatment was observed in patients treated with interferon β1-a sc tiw.
Disclosure: Annukka Murtonen: Nothing to disclose
Johanna Vuorio: Nothing to disclose
Elina Järvinen: employee of Merck Finland, an affiliate of Merck KGaA Darmstadt, Germany
Anna Wiksten: employee of StatFinn
Marja-Liisa Sumelahti: Nothing to disclose
Funding: Merck Finland
Abstract: EP1687
Type: ePoster
Abstract Category: Therapy - disease modifying - 28 Long-term treatment monitoring
Objective: To study the long-term real-life use of interferon β1-a sc tiw in relapsing remitting multiple sclerosis (RRMS) patients, and to investigate the duration of the treatment periods, the causes of treatment cessation, and changes in expanded disability status scale (EDSS).
Methods: Clinical data was drawn in two population based cohorts diagnosed for RRMS during 1990 to 2010 and 2010 to 2014. Patients treated with interferon β1-a sc tiw at the Tampere District University Hospital in Finland were included in the study. Baseline characteristics and study endpoints were summarized using descriptive statistics.
Results: Of the 680 patients diagnosed during 1990-2010, a total of 293 initiated with interferon β1-a sc tiw. The average first treatment period lasted 2.9 years (standard deviation SD 2.89). The EDSS at treatment start was 1.7 (mean, SD 1.56) and 3.4 at the follow up of 6.8 years (mean, SD 4.1).Of the 209 patients diagnosed during 2010-2014, a total of 68 initiated with interferon β1-a sc tiw. The average first treatment period lasted 2.1 years (SD 1.55). The EDSS at treatment start was 0.9 (mean, SD 1.08) and 1.3 at the follow up of 2.2 years (mean, SD 1.3).Of the 361 patients in both cohorts, 39.1 % of the patients did not switch treatment. A total of 36.1% switched treatment once. The activation of the disease was the most common cause for cessation of the treatment (24.1%). Other factors were low MXA titer (12.2%) and side effects (11.9%).A total of 53.7% did not have any treatment interruptions, 32.4% had one interruption.
Conclusions: Long-term compliance to treatment was observed in patients treated with interferon β1-a sc tiw.
Disclosure: Annukka Murtonen: Nothing to disclose
Johanna Vuorio: Nothing to disclose
Elina Järvinen: employee of Merck Finland, an affiliate of Merck KGaA Darmstadt, Germany
Anna Wiksten: employee of StatFinn
Marja-Liisa Sumelahti: Nothing to disclose
Funding: Merck Finland